Artificial nutrition in patients with cancer has no impact on tumour glucose metabolism: Results of the PETANC Study

Autor: Anne Fallières, Marie-Claude Eberlé, N. Flori, Hélène de Forges, Pierre Senesse, Julien Fraisse, Raphael Tetreau, Jean-Pierre Pouget, Sophie Guillemard, Pierre-Olivier Kotzki, Lore Santoro, Emmanuel Deshayes
Přispěvatelé: Institut de Recherche en Cancérologie de Montpellier (IRCM - U1194 Inserm - UM), CRLCC Val d'Aurelle - Paul Lamarque-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), CRLCC Val d'Aurelle - Paul Lamarque, Unité de biostatistiques, Centre Hospitalier Universitaire de Nîmes (CHU Nîmes), CCSD, Accord Elsevier
Rok vydání: 2019
Předmět:
Blood Glucose
Male
0301 basic medicine
medicine.medical_specialty
Cachexia
[SDV.CAN]Life Sciences [q-bio]/Cancer
030209 endocrinology & metabolism
Carbohydrate metabolism
Critical Care and Intensive Care Medicine
Gastroenterology
Enteral administration
Eating
03 medical and health sciences
0302 clinical medicine
[SDV.CAN] Life Sciences [q-bio]/Cancer
Fluorodeoxyglucose F18
Positron Emission Tomography Computed Tomography
Internal medicine
medicine
Humans
Prospective Studies
Nutritional support
Prospective cohort study
Aged
Cancer
Cancer staging
[SDV.MHEP] Life Sciences [q-bio]/Human health and pathology
030109 nutrition & dietetics
Nutrition and Dietetics
medicine.diagnostic_test
business.industry
Tumour growth
Middle Aged
medicine.disease
3. Good health
Glucose
Parenteral nutrition
Head and Neck Neoplasms
Positron emission tomography
Female
(18)F-FDG PET/CT
business
Supportive care
[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Zdroj: Clinical Nutrition
Clinical Nutrition, Elsevier, 2018, ⟨10.1016/j.clnu.2018.08.033⟩
ISSN: 0261-5614
Popis: Summary Background & aims Nutrition support is recommended in cachexic patients with cancer. However, there is no clear evidence about its impact on tumour growth. Glycolysis, which is usually higher in cancer than normal cells, can be monitored by 18F-fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG PET/CT) imaging that is widely used for cancer staging and therapy efficacy assessment. Here, we used 18F-FDG PET/CT imaging to investigate whether artificial nutrition has an impact on tumour glucose metabolism in patients with cancer and cachexia. Methods This prospective study included ten patients with histologically proven head and neck or oesophageal cancer. All patients underwent 18F-FDG PET/CT imaging at baseline and after (parenteral and/or enteral) nutrition support on average for 7 days. Tumour glucose metabolism changes were evaluated using static (SUVmax, SUVmean and SULpeak) and dynamic (glucose metabolic rate and transport constant rates, k) parameters computed from the 18F-FDG PET/CT data. Results Artificial nutrition (median energy intake of 21.83 kcal/kg/day [13.16–45.90], protein intake of 0.84 g/kg/day [0.56–1.64]) was administered. Eight patients (80%) received enteral nutrition and two patients (20%) parenteral support. Comparison of 18F-FDG PET/CT parameters did not highlight any significant difference in tumour glucose metabolism before and after the period of nutrition support. Conclusions In cachexic patients with head and neck or oesophageal cancer, nutrition support administered according to the current guidelines shows no impact on tumour glucose metabolism, assessed by 18F-FDG PET/CT.
Databáze: OpenAIRE
Externí odkaz: